Skip to main content
Figure 6 | BMC Neurology

Figure 6

From: Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hocanalyses of the EPOC trial

Figure 6

Clinical Global Impressions of Improvement scores. The figure shows the mean score for clinician impressions of overall improvement after 6 months of treatment. CGI-I, Clinical Global Impressions of Improvement; GA, glatiramer acetate; iDMT, injectable disease-modifying therapy; IFN, interferon; IM, intramuscular; SC, subcutaneous.

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us